Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
HORIBA, Ltd. is a Japanese precision instruments manufacturer specializing in automotive test systems, semiconductor manufacturing equipment, medical diagnostics, and environmental monitoring instruments. The company holds leading positions in automotive emissions testing equipment (critical for global emissions regulations compliance) and particle characterization instruments for semiconductor fabs. Stock performance is driven by automotive electrification trends, semiconductor capital equipment cycles, and environmental regulation enforcement globally.
HORIBA generates revenue through equipment sales with recurring income from consumables, service contracts, and calibration services. The company benefits from regulatory-driven demand (emissions standards like Euro 7, China 6b require sophisticated testing equipment) and installed base economics where service and parts generate 25-30% margins. Automotive segment has high switching costs due to OEM qualification cycles (18-24 months) and integration with vehicle development processes. Semiconductor exposure provides cyclical upside during capacity expansion phases, while medical diagnostics offers stable recurring revenue from reagent sales.
Global automotive production volumes and OEM R&D spending on emissions compliance and electrification testing infrastructure
Semiconductor capital equipment spending cycles, particularly memory and logic fab expansions in Taiwan, Korea, and China
Regulatory tightening of emissions standards (Euro 7 implementation timeline, US EPA rules, China environmental enforcement)
Japanese yen exchange rate fluctuations (70%+ revenue outside Japan, yen weakness boosts translated earnings)
Order backlog trends for large automotive test cell installations (€5-15M projects with 12-18 month lead times)
Automotive electrification transition reduces traditional ICE testing demand while EV/battery testing market remains fragmented with lower barriers to entry and pricing pressure
Semiconductor equipment commoditization risk as Chinese domestic suppliers gain share in metrology and process control segments, particularly for mature node fabs
Regulatory uncertainty around emissions standards timing (Euro 7 delays, potential US policy reversals) creates lumpy demand patterns and inventory risk
Concentration risk with top 20 customers representing estimated 40-50% of revenue, particularly Toyota, Volkswagen Group, and major semiconductor foundries
AVL List (Austria) and FEV Group compete aggressively in automotive powertrain testing with broader simulation software integration
Thermo Fisher Scientific and Agilent Technologies offer overlapping analytical instruments with larger service networks and cross-selling advantages
Chinese competitors (Focused Photonics, Sailhero) gaining share in environmental monitoring through government procurement preferences and 30-40% price discounts
Semiconductor metrology leaders KLA Corporation and Onto Innovation have superior R&D scale for advanced node process control
Limited balance sheet risk with 2.99x current ratio, 0.19x debt/equity, and strong cash generation (620% FCF yield appears anomalous, likely data quality issue - verify actual FCF/market cap ratio)
Pension obligations for Japanese workforce could pressure cash flow as demographic trends worsen, though specific unfunded liability not disclosed
Foreign exchange translation risk with 70%+ revenue in non-yen currencies but significant yen-denominated cost base creates natural hedge but earnings volatility
moderate-high - Automotive segment correlates with global light vehicle production (elasticity ~1.2x due to R&D spending volatility). Semiconductor exposure creates additional cyclicality tied to chip capex cycles. However, regulatory-driven demand provides partial buffer during downturns as emissions compliance remains mandatory. Medical diagnostics segment (~18% of revenue) offers counter-cyclical stability. Industrial production indices are strong leading indicators for 6-9 month forward revenue.
Rising rates have mixed impact: negative for customer capex decisions on large test cell installations (automotive OEMs and semiconductor fabs delay discretionary equipment purchases), but positive for yen carry trade dynamics that can weaken JPY and boost translated earnings. Customer financing costs affect order timing for multi-million dollar systems. Valuation multiple compression occurs as Japanese equities re-rate with global tech hardware peers during rate hiking cycles.
Moderate exposure through customer financial health. Automotive OEM credit stress delays equipment orders and extends payment terms. Semiconductor fab projects require strong sponsor balance sheets for multi-year commitments. Company maintains minimal debt (0.19x D/E) reducing direct financing risk, but customer access to credit affects large project awards. Tightening credit conditions correlate with 15-25% order intake declines in capital-intensive segments.
value-oriented investors seeking exposure to secular regulatory trends (emissions compliance) with cyclical upside from semiconductor and automotive recovery. Recent 83% one-year return suggests momentum investors have entered. Dividend yield likely modest (Japanese industrials typically 2-3%) attracting income-focused Japan equity funds. Low debt and strong FCF appeal to quality-focused managers. Limited US institutional ownership due to OTC listing and Japan small-cap liquidity constraints.
moderate-high - Beta likely 1.1-1.3x relative to Japanese equity indices due to cyclical end-market exposure and yen sensitivity. Quarterly earnings volatility driven by lumpy large project timing (single automotive test cell can represent 2-3% of quarterly revenue). ADR liquidity constraints amplify price swings. Semiconductor exposure adds volatility during capex cycle inflection points. Recent 21.6% three-month gain indicates elevated momentum-driven volatility.
